Literature DB >> 6318895

Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat.

M T Bardo, R K Bhatnagar, G F Gebhart.   

Abstract

Rats were implanted subcutaneously for 2-4 weeks with slow-release pellets of naltrexone (10 mg) or placebo and then the pellets were removed. One day after removal of the pellet, animals were either (1) sacrificed and various CNS regions examined for specific binding of [3H]naloxone, [3H]etorphine or [3H]rauwolscine or (2) they were anesthetized and prepared acutely for assessing morphine-induced changes in the spontaneous activity of neurons in the locus coeruleus (LC). Naltrexone treatment significantly increased the number of specific binding sites for opiates, but not for alpha 2-adrenergic antagonists, in spinal cord, hypothalamus, striatum and cortex. Specific binding of [3H]naloxone was also increased in the LC. The spontaneous activity of neurons in the LC was reduced by the chronic naltrexone treatment, suggesting that these neurons became supersensitive to the tonic inhibitory effect of endogenous opioid peptides. Moreover, neurons in the LC of chronic naltrexone-treated rats exhibited an enhanced response to the inhibitory effects of morphine administered systemically. These results demonstrate that chronic opiate receptor blockade increases the number of receptor sites for morphine and that this increase in receptors is accompanied by a neuronal supersensitivity in the LC to morphine which can be assessed electrophysiologically.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6318895     DOI: 10.1016/0006-8993(83)90023-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Involvement of mu-opioid receptors in the antitussive effects of pentazocine.

Authors:  J Kamei; K Katsuma; Y Kasuya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

2.  Increased sensitivity to rate-altering and discriminative stimulus effects of morphine following continuous exposure to naltrexone.

Authors:  A M Young; S R Mattox; M D Doty
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Conditioning of morphine-induced taste aversion and analgesia.

Authors:  J S Miller; K S Kelly; J L Neisewander; D F McCoy; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Treatment with isoproterenol of bupivacaine toxicity.

Authors:  P Lacombe; G Blaise; F Plante; C Hollmann
Journal:  Can J Anaesth       Date:  1990-05       Impact factor: 5.063

5.  Cognitive effects of high-dose naltrexone in patients with probable Alzheimer's disease.

Authors:  D S Knopman; M Hartman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

6.  Chronic naloxone increases opiate binding in SHR and WKY rats.

Authors:  E F Hahn
Journal:  Neurochem Res       Date:  1984-12       Impact factor: 3.996

7.  Naloxone-induced analgesia and morphine supersensitivity effects are contingent upon prior exposure to analgesic testing.

Authors:  C X Poulos; D M Knoke; A D Le; H Cappell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists.

Authors:  C A Paronis; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

9.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Authors:  Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien
Journal:  Arch Gen Psychiatry       Date:  2006-02

Review 10.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.